Medizinische Klinik und Poliklinik IV, LMU University Hospital, LMU Munich 80336, Germany.
Department of Endocrinology, Diabetology, and Clinical Nutrition, University Hospital Zürich (USZ) and University of Zurich (UZH), Zurich 8091, Switzerland.
Eur J Endocrinol. 2024 Sep 30;191(4):473-479. doi: 10.1093/ejendo/lvae127.
Cushing's syndrome (CS) can be difficult to diagnose. A timely diagnosis, however, is the cornerstone for targeted treatment, to reduce morbidity and mortality. One reason for the difficulties to identify early on patients with CS might be the presence of a mild phenotype. The aim of the study was to classify the phenotypic landscape of CS. We studied patients with overt CS and mild autonomous cortisol secretion (MACS).
The study was part of the German Cushing's registry. Patients were prospectively included at time of diagnosis and the number of comorbidities and clinical signs and symptoms were assessed in a standardized fashion. One hundred twenty-nine patients with CS (pituitary CS, n = 85, adrenal CS, n = 32, ectopic CS, n = 12, respectively) and 48 patients with MACS were included. Patients with clinical signs and/or comorbidities typical for CS and at least 2 pathological screening tests were classified as having CS. Patients with a 1 mg low-dose-dexamethasone-suppression test above 1.8 µg/dL without being clinically overt CS were classified as having MACS.
On average, patients with CS had 2 comorbidities (range 1-3) at time of diagnosis (pituitary CS: 2 [1-3], adrenal CS: 3 [2-4], ectopic CS: 3 [2-4]). Patients with MACS, however, had 3 comorbidities (range 2-3). Hypertension was the most common comorbidity in all subtypes of CS (78%-92%) and in patients with MACS (87%). Of a total of 11 clinical signs, patients with CS had on average 5 with 28% of patients having between 0 and 3 clinical signs, 50% 4-7 signs, and 22% more than 7 clinical signs. Patients with MACS had on average 2 clinical signs (range 1-3) at time of diagnosis.
The phenotypic landscape of CS is quite variable. The frequency of comorbidities is similar between patients with CS and MACS. A relevant number of patients with overt CS have just a few clinical signs. There is also an overlap in frequency of symptoms and clinical signs between patients with CS and MACS. According to the current guidelines, 96% of our patients with MACS fall into the category "consideration of adrenalectomy". This should be kept in mind when making treatment decisions in the latter group of patients.
库欣综合征(CS)的诊断较为困难。然而,及时诊断是进行靶向治疗的基础,这可以降低发病率和死亡率。早期识别 CS 患者存在困难的一个原因可能是存在轻度表型。本研究旨在对 CS 的表型谱进行分类。我们研究了显性 CS 和轻度自主皮质醇分泌(MACS)患者。
该研究是德国库欣登记处的一部分。患者在诊断时前瞻性纳入,以标准化方式评估合并症数量和临床体征及症状。共纳入 129 例 CS 患者(垂体 CS,n=85;肾上腺 CS,n=32;异位 CS,n=12)和 48 例 MACS 患者。具有 CS 典型临床体征和/或合并症且至少有 2 项病理筛查试验异常的患者被归类为 CS 患者。接受 1 mg 小剂量地塞米松抑制试验后,皮质醇>1.8μg/dL 但无显性 CS 的患者被归类为 MACS 患者。
CS 患者在诊断时平均有 2 种合并症(范围 1-3)(垂体 CS:2[1-3];肾上腺 CS:3[2-4];异位 CS:3[2-4])。然而,MACS 患者有 3 种合并症。高血压是所有 CS 亚型(78%-92%)和 MACS 患者(87%)最常见的合并症。在总共 11 种临床体征中,CS 患者平均有 5 种,其中 28%的患者有 0-3 种临床体征,50%的患者有 4-7 种,22%的患者有 7 种以上。MACS 患者在诊断时平均有 2 种临床体征(范围 1-3)。
CS 的表型谱变化较大。CS 患者和 MACS 患者的合并症发生率相似。相当一部分显性 CS 患者仅有少数临床体征。CS 患者和 MACS 患者的症状和体征也存在重叠。根据当前指南,我们的 MACS 患者中有 96%属于“考虑肾上腺切除术”类别。在制定后一组患者的治疗决策时应考虑到这一点。